Acacia Research (ACTG) Completes Asset Acquisition/Disposition
Ticker: ACTG · Form: 8-K · Filed: Jan 22, 2024 · CIK: 934549
| Field | Detail |
|---|---|
| Company | Acacia Research Corp (ACTG) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $57,078,670.12 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: acquisition, disposition, asset-change, corporate-action
TL;DR
**Acacia Research (ACTG) just completed a major asset deal, expect changes.**
AI Summary
Acacia Research Corporation (ACTG) filed an 8-K on January 22, 2024, to report the completion of an acquisition or disposition of assets on January 19, 2024. This filing indicates a significant change in the company's asset structure, which could impact its future revenue streams and operational focus. Investors should understand the specifics of this transaction, as it directly affects the company's financial health and strategic direction, potentially leading to new growth opportunities or a shift in its business model.
Why It Matters
This filing signals a material change in Acacia Research's business operations, which could alter its financial performance and future growth prospects. Investors need to know the details of the asset change to assess its impact on the company's valuation.
Risk Assessment
Risk Level: medium — The filing indicates a significant asset change without providing specific details, creating uncertainty about the nature and financial impact of the transaction.
Analyst Insight
Investors should seek further details on the specific assets acquired or disposed of by Acacia Research Corporation to understand the strategic implications and potential financial impact before making any investment decisions.
Key Players & Entities
- ACACIA RESEARCH CORPORATION (company) — the registrant filing the 8-K
- January 19, 2024 (date) — date of the earliest event reported (completion of acquisition/disposition)
- January 22, 2024 (date) — date the 8-K was filed
- ACTG (company) — trading symbol for Acacia Research Corporation
- The Nasdaq Stock Market, LLC (company) — exchange where ACTG Common Stock is registered
FAQ
What specific event did Acacia Research Corporation report in this 8-K filing?
Acacia Research Corporation reported the 'Completion of Acquisition or Disposition of Assets' as the earliest event on January 19, 2024, as per Item Information in the filing.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted to the SEC on January 22, 2024, as indicated by the 'FILED AS OF DATE' and 'DATE AS OF CHANGE' in the filing header.
What is the trading symbol and the exchange where Acacia Research Corporation's common stock is listed?
Acacia Research Corporation's common stock trades under the symbol 'ACTG' on 'The Nasdaq Stock Market, LLC', as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address and phone number of Acacia Research Corporation?
Acacia Research Corporation's business address is 767 Third Avenue, 6th Floor, New York, NY 10017, and its business phone number is (332) 236-8500, according to the 'BUSINESS ADDRESS' and 'BUSINESS PHONE' sections.
Is Acacia Research Corporation considered an emerging growth company according to this filing?
No, Acacia Research Corporation is not indicated as an emerging growth company, as the checkbox for 'Emerging growth company' is unchecked (o) in the filing.
Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2024-01-22 08:00:44
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ACTG The Nasdaq Stock Market,
- $57,078,670.12 — TW Biotech Opportunities Limited, for US$57,078,670.12 in aggregate (representing 1.43 per sha
Filing Documents
- actg-20240119.htm (8-K) — 22KB
- 0000934549-24-000003.txt ( ) — 146KB
- actg-20240119.xsd (EX-101.SCH) — 2KB
- actg-20240119_lab.xml (EX-101.LAB) — 24KB
- actg-20240119_pre.xml (EX-101.PRE) — 13KB
- actg-20240119_htm.xml (XML) — 3KB
01. Completion of Acquisition or Disposition of Assets
Item 2.01. Completion of Acquisition or Disposition of Assets On January 19, 2024, Acacia Research Corporation (the "Company") completed the sale of its 33,023,210 shares of Arix Bioscience PLC ("Arix") to RTW Biotech Opportunities Operating Ltd, a subsidiary of RTW Biotech Opportunities Limited, for US$57,078,670.12 in aggregate (representing 1.43 per share at an exchange rate of 1.2087 USD/GBP). Following the completion of the share sale, the Company no longer owns any shares of Arix.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 22, 2024 ACACIA RESEARCH CORPORATION By: /s/ Jason Soncini Name: Jason Soncini Title: General Counsel